Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.